ArticleTheranostics2022
Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Pooled it
- Circulating platelet-natural killer cell complexes are elevated in people living with human immunodeficiency virus on antiretroviral therapy.Journal of leukocyte biology · 2026Article
- Tumor-platelet cross talk in cancer: mechanisms, thrombotic risk, and translational opportunities.Blood advances · 2026Review
- Exploring platelet-covered and naked circulating tumor cells - a single-cell transcriptomic perspective.Journal of translational medicine · 2026Article
- Prognostic significance of circulating immune-inflammatory biomarkers IL-6 and systemic immune-inflammation index in hepatocellular carcinoma treated with immune checkpoint inhibitors: A meta-analysis.Journal of medical biochemistry · 2026Article
- Harmonizing definitions in liquid biopsy: A terminology framework by the international society of liquid biopsy.The journal of liquid biopsy · 2026Review
- Platelet-neutrophil cooperation in cancer: mechanisms of metastatic niche formation and implications for prognostic stratification and therapy.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Comprehensive circRNA profiling of platelets and exosomes identifies hsa_circ_0061274 as a novel biomarker for lung adenocarcinoma.Frontiers in immunology · 2026Article
- Non-coding RNAs in tumor-educated platelets: emerging roles in cancer progression, biomarker discovery, and therapeutic targeting.Frontiers in oncology · 2026Review
- The inhibitory action of camel urine on human platelet surface glycoproteins could be the potential mechanism for its reported anticancer effects.Frontiers in pharmacology · 2026Article
- A Darwinian Perspective on Tumor Evolution.International journal of biological sciences · 2026Review
- From escort to target, the multidimensional roles and prospects of platelets in tumor immune checkpoint inhibitor therapy.Frontiers in immunology · 2026Review
- Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets.European heart journal · 2025Article
- Unveiling the "Dark Matter" of platelet involvement in tumor microenvironment.Journal of pharmaceutical analysis · 2025Review
- Enhanced regenerative and developmental potential of embryonal and stem cell-derived platelets compared to adult platelets.Cell reports. Medicine · 2025Article
- Platelets in cancer and immunotherapy: functional dynamics and therapeutic opportunities.Experimental hematology & oncology · 2025Review
- Association of non-insulin-based insulin resistance indices, mean platelet volume and prostate cancer: a cross-sectional study.BMC cancer · 2025Article
- Gene Expression Profiling and Phenotypic Characterization of Circulating Tumor Cells Derived from a Murine Osteosarcoma Model.Cancers · 2025Article
- The FLNA Gene in Tumour-Educated Platelets Can Be Utilised to Identify High-Risk Populations for NSCLCs.Journal of cellular and molecular medicine · 2025Article
- Oncogenic KRASInternational journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 2 countries.
Alba Rodriguez-MartinezGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
Iris Simon-SaezGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
Sonia PeralesGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
Carmen Garrido-NavasGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
Alessandro RussoCenter for Thoracic Oncology. The Tisch Cancer Institute. Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Diego de Miguel-PerezCenter for Thoracic Oncology. The Tisch Cancer Institute. Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ignacio Puche-SanzGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
Clara AlaminosUrology Division, University Hospital of Jaén, Jaén, Spain.
Jorge CeronGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
Jose A LorenteGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
Maria Pilar MolinaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
Coral GonzalezGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
Massimo CristofanilliRobert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Alba Ortigosa-PalomoGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
Pedro J RealGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
Christian RolfoCenter for Thoracic Oncology. The Tisch Cancer Institute. Icahn School of Medicine at Mount Sinai, New York, NY, USA.
María J SerranoGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ESUniversidad de Granada · ESNorthwestern University · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Blood PlateletsNeoplastic Cells, CirculatingBiomarkers, TumorCell Line, TumorHumansLipidsMaleRNABiomarkers, TumorLipidsRNACD61circulating tumor cells (CTCs)epithelial-to-mesenchymal transition (EMT)platelet-educated tumors (PETs)Platelets
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.